|
BBS1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.88338275267597E-15 |
| Normal-vs-Stage2 |
1.91299999999783E-05 |
| Normal-vs-Stage3 |
3.08642000845794E-14 |
| Normal-vs-Stage4 |
1.95650162737593E-11 |
| Stage1-vs-Stage2 |
1.743380E-01 |
| Stage1-vs-Stage3 |
6.265800E-02 |
| Stage1-vs-Stage4 |
1.327560E-01 |
| Stage2-vs-Stage3 |
1.754200E-02 |
| Stage2-vs-Stage4 |
2.886400E-02 |
| Stage3-vs-Stage4 |
9.566800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.5719980872575E-11 |
| Normal-vs-AfricanAmerican |
4.663100E-03 |
| Normal-vs-Asian |
6.08879999752787E-08 |
| Caucasian-vs-AfricanAmerican |
7.348100E-02 |
| Caucasian-vs-Asian |
2.049000E-01 |
| AfricanAmerican-vs-Asian |
3.009800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.38218383591993E-14 |
| Normal-vs-Female |
1.62614366416847E-12 |
| Male-vs-Female |
2.325200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.66555658154266E-12 |
| Normal-vs-Age(41-60Yrs) |
2.50233167520264E-12 |
| Normal-vs-Age(61-80Yrs) |
5.69866376309847E-12 |
| Normal-vs-Age(81-100Yrs) |
7.98670000000667E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.949000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.666400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.734210E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.897800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.573170E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.515000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.273600E-02 |
| Classical-VS-Follicular |
9.079600E-01 |
| Classical-VS-Other |
5.175800E-01 |
| Classical-VS-Normal |
1.3550000010909E-09 |
| Tall-VS-Follicular |
3.857800E-02 |
| Tall-VS-Other |
6.302000E-01 |
| Tall-VS-Normal |
4.59460247625998E-11 |
| Follicular-VS-Other |
5.821000E-01 |
| Follicular-VS-Normal |
1.97770000376352E-09 |
| Other-VS-Normal |
2.282800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.32880381645373E-12 |
| Normal-vs-N1 |
1.46449519178304E-11 |
| N0-vs-N1 |
7.546100E-02 |
|
|
